RecruitingEarly Phase 1

Merck IIT: RRP Pembro and Lenvatinib

United States20 participantsStarted 2025-07-18

Plain-language summary

This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC)transfusion within last 2 weeks.
✓. Creatinine clearance (CrCl) should be calculated per institutional standard. -- Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies.

What they're measuring

Objective Response Rate (ORR)

Timeframe: At 12 weeks for up to 2 years and/or end of treatment

Adverse Events

Timeframe: Every 3 weeks for up to 2 years and/or end of treatment

Trial details

NCT IDNCT04645602

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

Contact for this trial

Sara Pai

203-836-0406 sara.pai@yale.edu

View on ClinicalTrials.gov More Human Papilloma Virus trials